Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET

Company Participants

AJ Bergmann - Chief Financial Officer

Linda Marban - Chief Executive Officer

Conference Call Participants

Joseph Pantginis - H.C. Wainright

Kristen Kluska - Cantor Fitzgerald

Aydin Huseynov - Ladenburg

Operator

Good afternoon, ladies and gentlemen, and welcome to Capricor Therapeutics Fourth Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Thursday, February 29, 2024.

I would now like to turn the conference over to AJ Bergmann, CFO of Capricor. Please go ahead.

AJ Bergmann

Thank you, and thank you for joining today. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies, our enrollment of patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates manufacturing capabilities, potential milestone payments, our financial position and our possible uses of existing cash and investment resources.

These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.

These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.

With that, I'll turn the call over to Linda Marban, CEO.

Linda Marban

Thanks, AJ. Good afternoon, and thank you for joining today's call. I'm encouraged with the progress we have made at Capricor in 2023 and into 2024. And today, I will outline our main priorities for our lead CAP-1002 program as well as provide a brief update on our exosome platform technology.

2023 was a big year for Capricor as we are now gearing up for biologics license application and commercialization. To that end, Capricor has assembled a team primarily focused on executing in four main areas in order to be prepared to bring our lead product, CAP-1002 to market for the treatment of DMD as expeditiously as possible.